HPR115 Patient and Provider Factors Associated with Filgrastim Biosimilar Uptake in the U.S.

Abstract

Biosimilars become available after the originator’s period of market exclusivity and offer the possibility of price competition. Biosimilar market uptake has so far been variable. We evaluated patient and provider factors associated with use of biosimilar filgrastim, the first biosimilar marketed in the US.